Purpose of this Study
We are doing this study to find out if an experimental drug called MK-2870 (the study drug) is a safe and effective option for people with cervical cancer. We want to see how well it works compared to the standard treatment for this diagnosis.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
- Have cancer that is metastatic (has spread) or has returned after treatment
- Have received at least one previous line of treatment that included an anti-PD-1/anti-PD-L1 therapy
What is Involved?
Description
If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 parts.
If you are in Part 1 of the study, you will take the study drug. If you are in Part 2 of the study, you will get another random assignment to 1 of 2 groups:
- If you are in Group 1, you will take the study drug.
- If you are in Group 2, you will receive the standard therapy that the study doctor believes is best for you. The standard drugs used to treat your form of cancer include: pemetrexed, tisotumab vedotin, topotecan, vinorelbine, gemcitabine, and irinotecan.
Study Details
Full Title
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to
Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of
Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic
Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of
Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic
Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
Principal Investigator
Angeles
Secord
Protocol Number
PRO00115757
NCT ID
NCT06459180
Phase
III
Enrollment Status
Open to Enrollment